Natera

Incyte

United Therapeutics

Gilead Sciences

Insmed

Neurocrine Biosciences

Vertex Pharmaceuticals

Alnylam Pharmaceuticals

AbbVie

Sarepta Therapeutics

SPDR S&P Biotech ETF

XBI tracks an equal-weighted index of US biotechnology stocks.

SPDR S&P Biotech ETF offers a buying opportunity after a recent decline and trades close to the 200-day moving average. XBI has a strong long-term track record, providing generous total returns for shareholders. The biotech sector is seeing increased levels of merger and acquisition deals, indicating potential undervaluation in biotech stocks.

XBI: 3 Reasons To Buy The Pullback And Hold This Biotech ETF Forever

Eli Lilly

Nuvectis Pharma

Schrodinger 

iShares Nasdaq Biotechnology ETF

What has been the top-performing stock so far of 2024? If you had said server installer Super Micro Computer (NASDAQ: SMCI ), that would be a great answer.

5 Healthcare Stocks to Buy for 2024

JPMorgan Equity Premium Income ETF

SPDR Portfolio High Yield Bond ETF

The SPDR Biotech ETF makes investing in the complicated biotechnology sector easy. The SPDR Portfolio High Yield Bond ETF generates a treasure trove of income from junk bonds.

3 Top ETFs I Plan to Buy in April

Madrigal Pharmaceuticals

Viking Therapeutics

After a strong resurgence in the back half of 2023 and continued momentum into the first quarter of 2024, biotech stocks are back in vogue. “Hawkish” Federal Reserve Policy, a brutal bear market in 2022, and investor preference for big tech stocks have meant underperformance for biotech stocks.

2 Top Biotech Buyout Candidates

Amgen

Pyxis Oncology

One of the best dip-buying opportunities in biotech stocks to buy was in Viking Therapeutics (NASDAQ: VKTX ). After hitting a high of $99.41, VKTX dipped back to about $60.30.

3 Biotech Stocks to Buy on the Dip: March 2024

Shares of biotechnology companies have been lagging behind the S&P 500 Index. This underperformance of XBI relative to the S&P 500, however, has only made the opportunity even more attractive to us. Evidence of improving fundamentals and rising mergers and acquisitions (M&A) activity within the biotechnology space has been underappreciated by investors.

XBI: Biotech Is A Strong Buy As M&A Activity Picks Up (Rating Upgrade)

ARK Genomic Revolution Multi-Sector ETF

Growth-focused investors may wish to set their sights on the hard-hit biotech stocks scene as rates begin to retreat, negative momentum settles and the industry catches a bit of a break for once. Of course, to get a higher chance at outsized gains, one must also have a high risk tolerance and a long-enough investment horizon.

3 Biotech ETFs Overdue for a Bounce

Hello! This week's ETF Wrap digs into the jump in biotech funds, as well as an “unusual” trend in U.S. small-cap stocks versus small-cap tech equities.

This biotech ETF sees ‘breakout' while U.S. small-cap technology stocks lag

The SPDR Biotech ETF (XBI) stock has surged hard in the past few weeks as investors cheer the recent FDA approvals and M&A activity in the industry. It has soared in the past four straight weeks and is sitting at its highest point since January 2022.

Here's why SPDR Biotech ETF (XBI) stock price is flying

VanEck Vectors Biotech ETF

Invesco Dynamic Biotechnology & Genome ETF

Look into how Biotech ETFs performed after Q4 earnings.

Where Are Biotech ETFs Headed After Q4 Earnings?

The thirty-month bear market in biopharmaceutical stocks ended last October. The subsequent rally was standard, beginning with acquisitions at generous premiums.

Biopharmaceutical Stocks: The Next Leg Of The Rally May Begin Soon

The U.S. Healthcare sector has shown strong growth and is projected to continue growing due to the increasing number of Americans entering Medicare. The SPDR S&P Biotech ETF invests in biotech and pharmaceutical companies and has a low yield of 0.02%. The abrdn Healthcare Opportunities Fund invests in global healthcare companies and has a higher yield of 7.3%, but relies on non-income sources to maintain its payout.

THQ Vs. XBI: Keeping The Biotech ETF For Now

The SPDR S&P Biotech ETF performance is more dependent on M&A than fundamental growth. The ETF has outperformed the NASDAQ since its inception but has seen a sharp decline since 2021 due to the end of zero-cost capital. The majority of the ETF's holdings are small-cap R&D startups, making it a speculative investment with limited fundamentals and valuations.

XBI: Biotech Speculation

Fidelity MSCI Health Care ETF

iShares U.S. Healthcare ETF

VanEck Vectors Pharmaceutical ETF

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

The healthcare sector presents a unique investment opportunity in 2024 due to attractive valuation and uncorrelated/robust cashflow of healthcare. Biopharma companies have pricing power and ability to adjust drug prices in line with inflation, providing advantage in inflationary environment.

Healthcare In 2024: Navigating The Biopharma Bull Run

BlackRock Health Sciences Trust II

Saba Capital Income & Opportunities Fund

Blackrock Floating Rate Income Strategies Fund Inc

abrdn Healthcare Investors 

Nuveen AMT-Free Municipal Value Fund

OFS Credit Company Inc

Invesco S&P 500 Equal Weight ETF

Special Opportunities Fund Inc

SPDR S&P 500 ETF Trust

Equity and fixed-income markets had another strong month in December, driven by continuing retreating risk-free Treasury rates. We even saw an improvement in the breadth of the overall market, with broader participation lifting some of the beaten-down sectors for the year. That said, closed-end fund discounts remain historically wide, and that continues to drive opportunity in the CEF wrapper.

5 Closed-End Fund Buys In The Month Of December 2023 (Plus 1 Sell)

Virtus LifeSci Biotech Products ETF

Bristol-Myers

Invesco Nasdaq Biotechnology ETF

Johnson & Johnson

Merck

The biotech space staged a strong comeback at the start of 2024, driven by multi-billion dollar deals, upbeat clinical results and cutting-edge medical advances like CRISPR gene-editing hitting prime-time.

Biotech ETFs Stage Solid Comeback at the Start of 2024

iShares U.S. Medical Devices ETF

VanEck Vectors Semiconductor ETF

Thematic exchange-traded funds have become extremely popular investing vehicles. These three growth-oriented thematic ETFs stand out as superb buys right now.

3 Thematic Growth ETFs to Load Up on Right Now

Ionis Pharma

Iovance Biotherapeutics

Intra-Cellular Therapies

Verve Therapeutics

The biotech sector is finishing 2023 on a high after a difficult couple of years, buoyed by Big Pharma M&A activity. The SPDR® S&P Biotech ETF has been soaring as a result of the M&A spree. Despite a challenging year, there have been some winners in the biotech sector - I have been fortunate to share a few successful tips with Seeking Alpha readers.

3 Biotech Bull Cases To Consider In 2024 - And 2 Wildcard Recommendations

ARK Innovation ETF

VanEck Vectors BDC Income ETF

Amplify Transformational Data Sharing ETF

Vanguard Total International Bond ETF

Manager Directed Portfolios - iM DBi Managed Futures Strategy ETF

iShares MSCI Emerging Markets ex China ETF

Fidelity Blue Chip Growth ETF

SPDR S&P China ETF

iShares Core MSCI Emerging Markets ETF

iShares Core S&P 500 ETF

Kraneshares Dynamic Emerging Markets Strategy ETF

AdvisorShares Pure US Cannabis ETF

Wisdomtree US Quality Growth Fund

Invesco QQQ

iShares 20+ Year Treasury Bond BuyWrite Strategy ETF

Vanguard S&P 500 ETF

Vanguard Short-Term Inflation-Protected Securities ETF

Vanguard FTSE Emerging Markets ETF

Technology Select Sector SPDR Fund

Hello! This is MarketWatch reporter Isabel Wang bringing you this week's ETF Wrap. In this week's edition, we look at ETF strategies that have exploded in popularity in 2023, and whether they will continue to gain momentum in the year ahead.

These ETF strategies were big winners in 2023. Here's where one CFRA analyst sees them going next year.

First Trust Health Care AlphaDEX Fund

iShares Global Healthcare ETF

The best healthcare ETFs patch investors into an area of the market that offers both defensive properties and long-term growth.

Best Healthcare ETFs to Buy Now

Shares have gotten a boost from the Fed and from M&A.

Biotech Stocks Are Breaking Out—and They Show No Sign of Slowing Down

United States Brent Oil Fund LP

Invesco DB Oil Fund

Direxion Daily S&P Oil & Gas Exp. & Prod. Bull 2X Shares

iShares U.S. Oil & Gas Exploration & Production ETF

VanEck Vectors Oil Services ETF

iPath Pure Beta Crude Oil ETN

Invesco Dynamic Oil & Gas Services ETF

ProShares Ultra Bloomberg Crude Oil

United States Oil Fund LP

SPDR S&P Oil & Gas Exploration & Production ETF

Here's our daily look at three charts linked to recent news-driven price moves, with key technical levels to monitor.

3 Charts For Investors to Watch Tuesday: Bitcoin, Oil, XBI ETF

AstraZeneca

BioMarin Pharmaceutical

Blueprint Medicines

Karuna Therapeutics Inc

Pfizer

Roche Holding AG

A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

Biotech stocks set for a rebound in 2024, analysts say

Biopharmaceutical sector valuations have become more attractive after a significant decline in 2021. Larger drug companies are making acquisitions and partnerships with small-cap stocks at generous premiums. Money managers are under-invested in the sector and may be pressured to add holdings before year-end, potentially fueling a significant upward move.

Biopharmaceutical Stocks: The Rally Has Just Begun

Biotech stocks have experienced a significant decline since February 2021, but better times are ahead due to several tailwinds. Scientific and medical breakthroughs, such as cell therapies, genetic medicines, and incretins in obesity, are creating large markets and revenue opportunities. M&A activity in the biotech industry, driven by big pharma companies seeking growth assets, is expected to provide opportunities for small and mid-cap biopharma companies.

Get Ready For The New Biotech Bull Market

News for SPDR S&P Biotech ETF ETF (XBI)